VolitionRx - executive interview

(2:52)

VolitionRx - executive interview

(16:44)

VolitionRx - executive interview

(9:12)

VolitionRx - executive interview

(8:2)

Executive Interview - VolitionRx

(8:11)

Executive Interview - VolitionRx

(3:48)

VolitionRx - executive interview

(13:10)

Executive interview - VolitionRx

(9:22)

Rethinking the approach to diagnose cancer: VolitionRx Limited (NYSE AMERICAN: VNRX) 重塑癌症診斷方法

(15:51)

Saving Lives and Improving Outcomes for People and Animals: Interview with the CEO of VolitionRx

(10:31)

VolitionRx Limited Full Fiscal Year 2022 Financial Results and Business Update

(12:57)

Volition signs exclusive license and supply agreement with Heska Corporation.

(5:46)

Second Quarter 2022 Financial Results \u0026 Business Update

(6:12)

VolitionRX Limited (NYSE American: VNRX): Virtual Investor Conferences

(29:25)

VolitionRx (VNRX) - Cameron Reynolds President \u0026 CEO

(25:12)

Volition expands availability of Nu.Q® Vet Cancer Test Through IDEXX Reference Laboratory Network

(3:16)

Cameron Reynolds - Volition RX

(4:6)

WVC 2023: Highlights

(4:13)

VolitionRx Breaks Down Supply Agreement of Nu.Q® Vet Cancer Tests with IDEXX Laboratories

(11:33)

Executive interview - VolitionRx

(7:36)

Business Update and Dr Tom Butera Introduction

(11:50)

VolitionRx Limited 2019 Full Year Earnings Results

(7:12)

Executive interview - VolitionRX discusses Q319 results and provides a business update

(7:56)

VolitionRx (VNRX) - Channelchek Takeaway Series - The J.P.Morgan Healthcare Conference

(34:21)

Cameron Reynolds, CEO - VolitionRx

(26:37)

VolitionRx Limited Full Fiscal Year 2023 Financial Results and Business Update

(12:19)

VolitionRx Discusses $28 Million Licensing Deal with Heska and Focus for 2022

(4:53)

VolitionRX seeks to revolutionise cancer diagnosis

(8:42)

Business Update with Cameron Reynolds

(5:20)